Developing innovative pricing structures and alternative fee agreement models that deliver additional value for our clients.
Advancing professional knowledge and offering credits for attorneys, staff and other professionals.
Helping clients respond correctly when a crisis occurs.
Providing our clients with legal, strategic, and practical advice to make transformational changes in their organizations.
Leveraging law and technology to deliver sound solutions.
Delivering seamless service through partnerships across the globe.
Leveraging leading-edge technology to guide change and create seamless, collaborative experiences for clients and attorneys.
Industry-leading conferences focused on affordable housing, tax credits, and more.
Providing actionable information to support strategic decision-making.
Teaming with clients to advance sustainable projects, mitigate the effects of climate change, and protect our planet.
Offering a range of investment management and fiduciary services.
Bringing together companies and investors for tomorrow’s new deals.
Offering fresh insights on cases that are delayed, over budget, or off-target from the desired resolution.
Courtroom-ready lawyers who can resolve disputes early on clients’ terms or prevail at trial before a judge or jury.
Creating positive impact in our communities through increasing equity, access, and opportunity.
David Resnick works with startup and established life sciences companies, as well as major U.S. research institutions, to develop comprehensive patent strategies to protect their intellectual property.
My practice is focused on strategic portfolio management, patent prosecution, transactional matters and associated client counseling. I manage the patent portfolios of some of the leading U.S. research institutions and domestic and international corporations. I also represent some of the world’s most recognized life sciences corporations before the U.S. Patent and Trademark Office. I have an extensive background in the life sciences space and have particular experience in the areas of microbiome related technologies, pharmacogenomics, disease biomarkers, proteomics, tissue engineering, gene therapy, regenerative medicine, drug delivery systems, stem cells, angiogenesis modulation, cancer vaccines, oncology, immune modulation, medical devices, and diagnostics.
I’ve written articles on patent prosecution practice, personalized medicine and technology issues for Nature Biotechnology, The Journal of Biolaw & Business, Personalized Medicine and other publications. I’m also a member of the editorial board of Pharmaceutical Patent Analyst.
I regularly assist clients in building and evaluating their intellectual property portfolios as well as in evaluating the intellectual property held by competitors. I regularly conduct freedom-to-operate analyses and prepare infringement and validity opinions involving complex and cutting-edge technologies.
I assist clients with patent prosecution in the areas of:
I work closely with my clients to identify and analyze acquisition targets and regularly conduct due diligence related to potential acquisitions.
In the aftermath of the Prometheus decision, and until such time as further judicial decisions provide greater clarity, I foresee that many life sciences companies will continue to struggle with respect to what qualifies as patent-eligible subject matter.
This media clip highlights the Wheelchair Man book launch party hosted at the Nixon Peabody Boston office and features pro bono client, Mohammed Sayed (AKA Wheelchair Man). Boston IP counseling & transactions partner David Resnick and public company transactions associate Tevia Pollard helped Mohammed create his new non-profit RimPower.
U.S. District Court, District of Massachusetts
U.S. Court of Appeals, Federal Circuit
U.S. Patent and Trademark Office
Syracuse University College of Law, J.D.
University of Rhode Island, B.S., Microbiology
University of Rhode Island, M.S., Microbiology
David is a member of the Association of University Technology Managers and the American Intellectual Property Law Association. David is also a member of the Personalized Medicine Coalition’s Public Policy Committee.
Subscribe to stay informed of the latest legal news, alerts, and business trends.Subscribe